Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells

PLoS Computational Biology

Volumn 12, Issue 8, 2016, Pages

  Merkle, Ruth ^a,b   Steiert, Bernhard ^c   Salopiata, Florian ^a,b   Depner, Sofia ^a,b   Raue, Andreas ^c,d   Iwamoto, Nao ^a   Schelker, Max ^c,e   Hass, Helge ^c   Wäsch, Marvin ^a,b   Böhm, Martin E ^a   Mücke, Oliver ^a   Lipka, Daniel B ^a   Plass, Christoph ^a   Lehmann, Wolf D ^a   Kreutz, Clemens ^c   Timmer, Jens ^c   Schilling, Marcel ^a   Klingmüller, Ursula ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b German Center for Lung Research (DZL)   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d MERRIMACK PHARMACEUTICALS   (United States)

^e HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; CANCER CELLS; CELL CULTURE; CELL DEATH; CELL SIGNALING; DISEASES; GENES; MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; SIGNALING;

CELL TYPES; CIS-PLATIN; CISPLATIN; COLONY FORMING UNITS; ERYTHROPOIETIN RECEPTORS; LUNG CANCER; NON-SMALL-CELL LUNG CARCINOMATA; PROGENITOR CELL; REAL-TIME PCR; RECEPTOR SIGNALING;

CHEMOTHERAPY;

CISPLATIN; ERYTHROPOIETIN RECEPTOR; JANUS KINASE; MESSENGER RNA; STAT PROTEIN;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CELLULAR PARAMETERS; COLONY FORMING UNIT; CONTROLLED STUDY; ERYTHROID PRECURSOR CELL; GENE TARGETING; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; MATHEMATICAL MODEL; SIGNAL TRANSDUCTION; SIMULATION; BIOLOGY; CLASSIFICATION; CYTOLOGY; ERYTHROID CELL; GENETICS; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PHYSIOLOGY; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; ERYTHROID CELLS; HUMANS; LUNG NEOPLASMS; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION;

EID: 84988965389     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1005049     Document Type: Article

References (67)

1. Bender E, Epidemiology: The dominant malignancy. Nature. 2014;513(7517):S2–3. doi: 10.1038/513S2a25208070.
2. Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22(39):8031–41. doi: 10.1038/sj.onc.120692812970751.
3. Wood PA, Hrushesky WJ, Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995;95(4):1650–9. doi: 10.1172/JCI1178407706473; PubMed Central PMCID: PMC295669.
4. Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol. 1998;9(3):255–60. 9602258.
5. Zhu H, Jackson T, Bunn HF, Detecting and responding to hypoxia. Nephrol Dial Transplant. 2002;17Suppl 1:3–7. 11812905; PubMed Central PMCID: PMCPMC3044474.
6. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25(9):1027–32. doi: 10.1200/JCO.2006.07.151417312332.
7. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 2001;61(9):3561–5. 11325818.
8. Dagnon K, Pacary E, Commo F, Antoine M, Bernaudin M, Bernaudin JF, et al. Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res. 2005;11(3):993–9. 15709164.
9. Dunlop EA, Percy MJ, Boland MP, Maxwell AP, Lappin TR, Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin. Neurodegener Dis. 2006;3(1–2):94–100. doi: 10.1159/00009209916909043.
10. Doleschel D, Mundigl O, Wessner A, Gremse F, Bachmann J, Rodriguez A, et al. Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts. J Nucl Med. 2012;53(2):304–11. doi: 10.2967/jnumed.111.09112422228796.
11. Saintigny P, Besse B, Callard P, Vergnaud AC, Czernichow S, Colombat M, et al. Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin Cancer Res. 2007;13(16):4825–31. doi: 10.1158/1078-0432.Ccr-06-3061. WOS:000248837900024. 17699861
12. Brown WM, Maxwell P, Graham AN, Yakkundi A, Dunlop EA, Shi Z, et al. Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells. 2007;25(3):718–22. Epub 2006 Nov 16. doi: 10.1634/stemcells.2006-068717110616.
13. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG, Expression and function of erythropoietin receptors in tumors—Implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer. 2007;110(3):477–88. doi: 10.1002/cncr.22832. WOS:000248206700002. 17582631
14. Kumar SM, Zhang G, Bastian BC, Arcasoy MO, Karande P, Pushparajan A, et al. Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene. 2012;31(13):1649–60. doi: 10.1038/onc.2011.36621860424; PubMed Central PMCID: PMC3441831.
15. Becker V, Sengupta D, Ketteler R, Ullmann GM, Smith JC, Klingmuller U, Packing density of the erythropoietin receptor transmembrane domain correlates with amplification of biological responses. Biochemistry. 2008;47(45):11771–82. doi: 10.1021/bi801425e18855427.
16. Remy I, Wilson IA, Michnick SW, Erythropoietin receptor activation by a ligand-induced conformation change. Science. 1999;283(5404):990–3. 9974393.
17. Hebenstreit D, Horejs-Hoeck J, Duschl A, JAK/STAT-dependent gene regulation by cytokines. Drug News Perspect. 2005;18(4):243–9. doi: 10.1358/dnp.2005.18.4.90865816034480.
18. Yasukawa H, Sasaki A, Yoshimura A, Negative regulation of cytokine signaling pathways. Annu Rev Immunol. 2000;18:143–64. doi: 10.1146/annurev.immunol.18.1.14310837055.
19. Bachmann J, Raue A, Schilling M, Bohm ME, Kreutz C, Kaschek D, et al. Division of labor by dual feedback regulators controls JAK2/STAT5 signaling over broad ligand range. Mol Syst Biol. 2011;7:516. doi: 10.1038/msb.2011.5021772264; PubMed Central PMCID: PMCPMC3159971.
20. Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, Yoshimura A, CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem. 2000;275(38):29338–47. doi: 10.1074/jbc.M00345620010882725.
21. Hilton DJ, Negative regulators of cytokine signal transduction. Cell Mol Life Sci. 1999;55(12):1568–77. 10526574.
22. Klingmüller U, Lorenz U, Cantley LC, Neel BG, Lodish HF, Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell. 1995;80(5):729–38. 7889566.
23. Schilling M, Maiwald T, Hengl S, Winter D, Kreutz C, Kolch W, et al. Theoretical and experimental analysis links isoform-specific ERK signalling to cell fate decisions. Mol Syst Biol. 2009;5:334. doi: 10.1038/msb.2009.9120029368; PubMed Central PMCID: PMC2824492.
24. Huo X, Ni X, When do stepwise algorithms meet subset selection criteria?Ann Statist. 2007;35:870–87.
25. Tibshirani R, Regression shrinkage and selection via the Lasso. J Roy Stat Soc B Met. 1996;58(1):267–88. WOS:A1996TU31400017.
26. Zou H, Hastie T, Regularization and variable selection via the elastic net. J R Stat Soc Series B. 2005;67:301–20.
27. Guyon I, An Introduction to Variable and Feature Selection. J Mach Learn Res. 2003;3:1157–82.
28. Mao KZ, Orthogonal forward selection and backward elimination algorithms for feature subset selection. IEEE Trans Syst Man Cybern B Cybern. 2004;34(1):629–34. 15369099.
29. Ng AY. Feature selection, L1 vs. L2 regularization, and rotational invariance. Proceedings of the twenty-first international conference on Machine learning; Banff, Alberta, Canada. 1015435: ACM; 2004. p. 78.
30. Hastie TJ, Tibshirani RJ, Friedman JH, The Elements of Statistical Learning: Data Mining, Inference and Prediction: Springer; 2001.
31. Raue A, Steiert B, Schelker M, Kreutz C, Maiwald T, Hass H, et al. Data2Dynamics: a modeling environment tailored to parameter estimation in dynamical systems. Bioinformatics. 2015. doi: 10.1093/bioinformatics/btv40526142188.
32. Schmidt M, Fung G, Rosales R. Optimization methods for L1-regularization. University of British Columbia, Technical Report TR-2009. 2009;19.
33. Elliott S, Swift S, Busse L, Scully S, Van G, Rossi J, et al. Epo receptors are not detectable in primary human tumor tissue samples. PLoS One. 2013;8(7):e68083. doi: 10.1371/journal.pone.006808323861852; PubMed Central PMCID: PMC3701640.
34. Schilling M, Maiwald T, Bohl S, Kollmann M, Kreutz C, Timmer J, et al. Computational processing and error reduction strategies for standardized quantitative data in biological networks. FEBS J. 2005;272(24):6400–11. doi: 10.1111/j.1742-4658.2005.05037.x16336276.
35. Raue A, Kreutz C, Maiwald T, Bachmann J, Schilling M, Klingmuller U, et al. Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood. Bioinformatics. 2009;25(15):1923–9. doi: 10.1093/bioinformatics/btp35819505944.
36. Swameye I, Muller TG, Timmer J, Sandra O, Klingmuller U, Identification of nucleocytoplasmic cycling as a remote sensor in cellular signaling by databased modeling. Proc Natl Acad Sci U S A. 2003;100(3):1028–33. doi: 10.1073/pnas.023733310012552139; PubMed Central PMCID: PMC298720.
37. Raue A, Schilling M, Bachmann J, Matteson A, Schelker M, Kaschek D, et al. Lessons learned from quantitative dynamical modeling in systems biology. PLoS One. 2013;8(9):e74335. doi: 10.1371/journal.pone.007433524098642; PubMed Central PMCID: PMC3787051.
38. Hass H, Kreutz C, Timmer J, Kaschek D, Fast integration-based prediction bands for ordinary differential equation models. Bioinformatics. 2015. doi: 10.1093/bioinformatics/btv74326685309.
39. Kreutz C, Raue A, Timmer J, Likelihood based observability analysis and confidence intervals for predictions of dynamic models. BMC Syst Biol. 2012;6:120. doi: 10.1186/1752-0509-6-12022947028; PubMed Central PMCID: PMCPMC3490710.
40. Todaro M, Turdo A, Bartucci M, Iovino F, Dattilo R, Biffoni M, et al. Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy. Cancer Res. 2013;73(21):6393–400. doi: 10.1158/0008-5472.CAN-13-024824008319.
41. Hattangadi SM, Wong P, Zhang L, Flygare J, Lodish HF, From stem cell to red cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications. Blood. 2011;118(24):6258–68. doi: 10.1182/blood-2011-07-35600621998215; PubMed Central PMCID: PMC3236116.
42. Shen-Orr SS, Tibshirani R, Khatri P, Bodian DL, Staedtler F, Perry NM, et al. Cell type-specific gene expression differences in complex tissues. Nat Methods. 2010;7(4):287–9. doi: 10.1038/nmeth.143920208531; PubMed Central PMCID: PMCPMC3699332.
43. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150(6):1121–34. doi: 10.1016/j.cell.2012.08.02422980976; PubMed Central PMCID: PMCPMC3656590.
44. Wisniewski JR, Vildhede A, Noren A, Artursson P, In-depth quantitative analysis and comparison of the human hepatocyte and hepatoma cell line HepG2 proteomes. J Proteomics. 2016;136:234–47. doi: 10.1016/j.jprot.2016.01.01626825538.
45. Pan C, Kumar C, Bohl S, Klingmueller U, Mann M, Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions. Mol Cell Proteomics. 2009;8(3):443–50. doi: 10.1074/mcp.M800258-MCP20018952599; PubMed Central PMCID: PMCPMC2649808.
46. Huang LJ, Constantinescu SN, Lodish HF, The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell. 2001;8(6):1327–38. 11779507.
47. Timney BL, Tetenbaum-Novatt J, Agate DS, Williams R, Zhang W, Chait BT, et al. Simple kinetic relationships and nonspecific competition govern nuclear import rates in vivo. J Cell Biol. 2006;175(4):579–93. doi: 10.1083/jcb.20060814117116750; PubMed Central PMCID: PMCPMC2064595.
48. Hoyt R, Zhu W, Cerignoli F, Alonso A, Mustelin T, David M, Cutting edge: selective tyrosine dephosphorylation of interferon-activated nuclear STAT5 by the VHR phosphatase. J Immunol. 2007;179(6):3402–6. 17785772; PubMed Central PMCID: PMCPMC2770724.
49. He B, You L, Uematsu K, Zang KL, Xu ZD, Lee AY, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. P Natl Acad Sci USA. 2003;100(24):14133–8. doi: 10.1073/pnas.2232790100. WOS:000186803800070.
50. Wilusz CJ, Wormington M, Peltz SW, The cap-to-tail guide to mRNA turnover. Nat Rev Mol Cell Biol. 2001;2(4):237–46. doi: 10.1038/3506702511283721.
51. Danko CG, Hah N, Luo X, Martins AL, Core L, Lis JT, et al. Signaling pathways differentially affect RNA polymerase II initiation, pausing, and elongation rate in cells. Mol Cell. 2013;50(2):212–22. doi: 10.1016/j.molcel.2013.02.01523523369; PubMed Central PMCID: PMCPMC3640649.
52. Hornberg JJ, Westerhoff HV, Oncogenes are to lose control on signaling following mutation: should we aim off target?Mol Biotechnol. 2006;34(2):109–16. doi: 10.1385/MB:34:2:10917172656.
53. Zhou B, Damrauer JS, Bailey ST, Hadzic T, Jeong Y, Clark K, et al. Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. J Clin Invest. 2014;124(2):553–63. doi: 10.1172/JCI6980424435044; PubMed Central PMCID: PMC3904607.
54. Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015;1(5):643–51. doi: 10.1001/jamaoncol.2015.159026181658.
55. Geyer HL, Mesa RA, Therapy for myeloproliferative neoplasms: when, which agent, and how?Blood. 2014;124(24):3529–37. doi: 10.1182/blood-2014-05-57763525472969.
56. Buchert M, Burns CJ, Ernst M, Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene. 2016;35(8):939–51. doi: 10.1038/onc.2015.15025982279.
57. Kinsella TM, Nolan GP, Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther. 1996;7(12):1405–13. doi: 10.1089/hum.1996.7.12-14058844199.
58. Ketteler R, Glaser S, Sandra O, Martens UM, Klingmuller U, Enhanced transgene expression in primitive hematopoietic progenitor cells and embryonic stem cells efficiently transduced by optimized retroviral hybrid vectors. Gene Ther. 2002;9(8):477–87. doi: 10.1038/sj.gt.330165311948372.
59. Becker V, Schilling M, Bachmann J, Baumann U, Raue A, Maiwald T, et al. Covering a broad dynamic range: information processing at the erythropoietin receptor. Science. 2010;328(5984):1404–8. doi: 10.1126/science.118491320488988.
60. Schneider CA, Rasband WS, Eliceiri KW, NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671–5. 22930834.
61. Raia V, Schilling M, Bohm M, Hahn B, Kowarsch A, Raue A, et al. Dynamic mathematical modeling of IL13-induced signaling in Hodgkin and primary mediastinal B-cell lymphoma allows prediction of therapeutic targets. Cancer Res. 2011;71(3):693–704. doi: 10.1158/0008-5472.CAN-10-298721127196.
62. Boehm ME, Hahn B, Lehmann WD, One-source peptide/phosphopeptide ratio standards for accurate and site-specific determination of the degree of phosphorylation. Methods Mol Biol. 2014;1156:367–78. doi: 10.1007/978-1-4939-0685-7_2424792001.
63. Boehm ME, Adlung L, Schilling M, Roth S, Klingmuller U, Lehmann WD, Identification of isoform-specific dynamics in phosphorylation-dependent STAT5 dimerization by quantitative mass spectrometry and mathematical modeling. J Proteome Res. 2014;13(12):5685–94. doi: 10.1021/pr500692325333863.
64. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A. 2005;102(44):15785–90. doi: 10.1073/pnas.050781610216243968; PubMed Central PMCID: PMCPMC1276092.
65. Hindmarsh AC, Brown PN, Grant KE, Lee SL, Serban R, Shumaker DE, et al. SUNDIALS: Suite of nonlinear and differential/algebraic equation solvers. ACM Trans Math Softw. 2005;31(3):363–96. doi: 10.1145/1089014.1089020
66. Coleman TF, Li Y, An interior trust region approach for nonlinear minimization subject to bounds. SIAM J Optim. 1996;6(2):418–45.
67. Kreutz C, Bartolome Rodriguez MM, Maiwald T, Seidl M, Blum HE, Mohr L, et al. An error model for protein quantification. Bioinformatics. 2007;23(20):2747–53. doi: 10.1093/bioinformatics/btm39717768165.